European Investor
27 Jul 2026, 16:04
AstraZeneca Stock Edges Higher After Strong Earnings and Reaffirms 2026 Outlook
AstraZeneca (NASDAQ: AZN) shares rose about 1% in early trading on Monday after the pharmaceutical giant reported solid second-quarter results, driven by continued strength in its oncology and rare disease businesses while reaffirming its full-year guidance.
The company reported second-quarter revenue of $15.4 billion, up 6% year over year, while core earnings per share climbed 21% to $2.63. For the first half of 2026, total revenue increased 6% and core EPS rose 11%, supported by double-digit growth in Oncology and Rare Disease, partially offset by the loss of exclusivity for Farxiga in the U.S. and pricing headwinds in China.
Management reaffirmed its 2026 outlook, continuing to expect total revenue growth in the mid-to-high single-digit percentage range and low double-digit growth in core EPS at constant exchange rates. CEO Pascal Soriot also reiterated confidence in AstraZeneca's long-term strategy, noting that the company remains on track to achieve its ambition of reaching $80 billion in annual revenue by 2030 despite recent pipeline setbacks.
Investors also welcomed AstraZeneca's continued pipeline progress. Since its previous earnings report, the company has secured 30 regulatory approvals across major markets and reported several positive Phase III trial results, reinforcing confidence in its future product portfolio.
The modest gain in AstraZeneca shares reflects investor confidence in the company's ability to deliver consistent earnings growth, supported by a diversified portfolio of blockbuster medicines, an active clinical pipeline, and disciplined execution despite ongoing industry pricing and patent challenges.
AstraZeneca (NASDAQ: AZN) shares rose about 1% in early trading on Monday after the pharmaceutical giant reported solid second-quarter results, driven by continued strength in its oncology and rare disease businesses while reaffirming its full-year guidance.
The company reported second-quarter revenue of $15.4 billion, up 6% year over year, while core earnings per share climbed 21% to $2.63. For the first half of 2026, total revenue increased 6% and core EPS rose 11%, supported by double-digit growth in Oncology and Rare Disease, partially offset by the loss of exclusivity for Farxiga in the U.S. and pricing headwinds in China.
Management reaffirmed its 2026 outlook, continuing to expect total revenue growth in the mid-to-high single-digit percentage range and low double-digit growth in core EPS at constant exchange rates. CEO Pascal Soriot also reiterated confidence in AstraZeneca's long-term strategy, noting that the company remains on track to achieve its ambition of reaching $80 billion in annual revenue by 2030 despite recent pipeline setbacks.
Investors also welcomed AstraZeneca's continued pipeline progress. Since its previous earnings report, the company has secured 30 regulatory approvals across major markets and reported several positive Phase III trial results, reinforcing confidence in its future product portfolio.
The modest gain in AstraZeneca shares reflects investor confidence in the company's ability to deliver consistent earnings growth, supported by a diversified portfolio of blockbuster medicines, an active clinical pipeline, and disciplined execution despite ongoing industry pricing and patent challenges.
